71 related articles for article (PubMed ID: 3103522)
1. [Treatment of cyclic attacks of acute intermittent porphyria with an LH-RH agonist administered by the intranasal route].
Semon C; Dupond JL; Mallet H; Grandmottet-Cambefort C; Humbert P
Ann Endocrinol (Paris); 1986; 47(5):399-402. PubMed ID: 3103522
[TBL] [Abstract][Full Text] [Related]
2. Premenstrual exacerbations in hepatic porphyria: prevention by intermittent administration of an LH-RH agonist in combination with a gestagen.
Bargetzi MJ; Meyer UA; Birkhaeuser MH
JAMA; 1989 Feb; 261(6):864. PubMed ID: 2492353
[No Abstract] [Full Text] [Related]
3. [The effects of intranasal application of low dose buserelin in women with hypothalamic amenorrhea].
Takeuchi H; Okabe C; Iida M; Fukuda M; Takada M
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Feb; 44(2):167-73. PubMed ID: 1545170
[TBL] [Abstract][Full Text] [Related]
4. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
Nillius SJ; Bergquist C; Wide L
Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
[TBL] [Abstract][Full Text] [Related]
5. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
6. Interference in follicular maturation following acute intranasal LH-RH agonist administration during mid and late follicular phase.
Lemay A; Faure N
Int J Fertil; 1988; 33(1):60-7. PubMed ID: 2896176
[TBL] [Abstract][Full Text] [Related]
7. Acute intermittent porphyria treated by testosterone implant.
Savage MW; Reed P; Orrman-Rossiter SL; Weinkove C; Anderson DC
Postgrad Med J; 1992 Jun; 68(800):479-81. PubMed ID: 1437936
[TBL] [Abstract][Full Text] [Related]
8. A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria.
Anderson KE; Spitz IM; Bardin CW; Kappas A
Arch Intern Med; 1990 Jul; 150(7):1469-74. PubMed ID: 2196028
[TBL] [Abstract][Full Text] [Related]
9. Peptide contraception in women. Inhibition of ovulation by chronic intranasal LRH agonist therapy.
Bergquist C; Nillius SJ; Wide L
Ups J Med Sci; 1984; 89(2):99-106. PubMed ID: 6431676
[TBL] [Abstract][Full Text] [Related]
10. Luteinizing hormone releasing hormone agonist for contraception in breast feeding women.
Fraser HM; Dewart PJ; Smith SK; Cowen GM; Sandow J; McNeilly AS
J Clin Endocrinol Metab; 1989 Nov; 69(5):996-1002. PubMed ID: 2507572
[TBL] [Abstract][Full Text] [Related]
11. Treatment with a gonadotropin-releasing hormone agonist in acne or idiopathic hirsutism.
Faloia E; Filipponi S; Mancini V; Morosini P; De Pirro R
J Endocrinol Invest; 1993 Oct; 16(9):675-7. PubMed ID: 8282961
[TBL] [Abstract][Full Text] [Related]
12. Danazol administration to females with menses-associated exacerbations of acute intermittent porphyria.
Lamon JM; Frykholm BC; Herrera W; Tschudy DP
J Clin Endocrinol Metab; 1979 Jan; 48(1):123-6. PubMed ID: 422693
[TBL] [Abstract][Full Text] [Related]
13. LHRH analogue treatment for the prevention of premenstrual attacks of acute porphyria.
Herrick AL; McColl KE; Wallace AM; Moore MR; Goldberg A
Q J Med; 1990 Apr; 75(276):355-63. PubMed ID: 2117297
[TBL] [Abstract][Full Text] [Related]
14. Normal adults and subjects with hypogonadotropic hypogonadism respond differently to D-Ser(TBU)6-LH-RH-EA10.
Smith R; Donald RA; Espiner EA; Stronach SG; Edwards IA
J Clin Endocrinol Metab; 1979 Jan; 48(1):167-70. PubMed ID: 106067
[TBL] [Abstract][Full Text] [Related]
15. Intranasal LHRH agonist (Buserelin) after ovulation: a post-coital contraceptive approach.
Lemay A; Faure N; Labrie F; Fazekas AT
Contracept Deliv Syst; 1983 Apr; 4(2):107-25. PubMed ID: 12338631
[TBL] [Abstract][Full Text] [Related]
16. LHRH analogues for hormonal manipulation in acute intermittent porphyria.
Anderson KE
Semin Hematol; 1989 Jan; 26(1):10-5. PubMed ID: 2646719
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty.
Holland FJ; Fishman L; Costigan DC; Luna L; Leeder S
J Clin Endocrinol Metab; 1986 Nov; 63(5):1065-70. PubMed ID: 3093518
[TBL] [Abstract][Full Text] [Related]
18. [Androgens and other hormones in buserelin therapy].
Fuchs U; Zwirner M
Geburtshilfe Frauenheilkd; 1991 Feb; 51(2):140-2. PubMed ID: 1904040
[TBL] [Abstract][Full Text] [Related]
19. Effect of gonadorelin, lecirelin, and buserelin on LH surge, ovulation, and progesterone in cattle.
Picard-Hagen N; Lhermie G; Florentin S; Merle D; Frein P; Gayrard V
Theriogenology; 2015 Jul; 84(2):177-83. PubMed ID: 25890780
[TBL] [Abstract][Full Text] [Related]
20. Pituitary and ovarian response to acute stimulation with LH-RH in normal and anovulatory women.
Aparicio NJ; Casas PR; Galimberti DM; de Laborde NP; Badano A; García EP; Meichi HR; Mirkin A; Szejner M; Jaitt A; Margulies M; Rosner JM
Int J Fertil; 1977; 22(1):6-15. PubMed ID: 18416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
